Table 3. . Pooled risk ratios for specific immune-related all-grade adverse events.
| Adverse events | Studies (n) | Chemoimmunotherapy | Chemotherapy | Pooled RR (95% CI) | I2 (%) | p-value | ||
|---|---|---|---|---|---|---|---|---|
| Events | Total | Events | Total | |||||
| Hypothyroidism | 6 | 226 | 2174 | 35 | 1716 | 5.18 (2.89–9.27) | 51 | 0.00001 |
| Hyperthyroidism | 6 | 92 | 2174 | 18 | 1716 | 3.73 (1.70–8.19) | 50 | 0.001 |
| Colitis | 6 | 41 | 2174 | 7 | 1716 | 3.46 (1.60–7.47) | 0 | 0.002 |
| Pneumonitis | 6 | 117 | 2174 | 30 | 1716 | 2.92 (1.95–4.37) | 0 | 0.00001 |
| Hepatitis | 6 | 135 | 2174 | 50 | 1716 | 2.41 (1.27–4.60) | 52 | 0.007 |
| Diabetes | 4 | 10 | 1605 | 3 | 1162 | 1.77 (0.56–5.59) | 0 | 0.33 |
| Pancreatitis | 4 | 14 | 1562 | 3 | 1102 | 2.35 (0.75–7.41) | 0 | 0.14 |
| Severe skin reaction | 4 | 21 | 1367 | 9 | 1150 | 1.63 (0.68–3.88) | 12 | 0.27 |
| Infusion reaction | 4 | 28 | 1308 | 10 | 1090 | 2.11 (1.02–4.37) | 0 | 0.04 |
| Adrenal insufficiency | 3 | 10 | 1271 | 4 | 828 | 1.12 (0.23–5.39) | 23 | 0.89 |
| Rash | 3 | 258 | 1018 | 149 | 1002 | 1.68 (1.13–2.50) | 78 | 0.01 |
| Hypophysitis | 3 | 9 | 1076 | 0 | 876 | 5.57 (1.01–30.76) | 0 | 0.05 |
| Nephritis | 3 | 12 | 1076 | 2 | 876 | 2.57 (0.62–10.59) | 0 | 0.19 |
| Meningoencephalitis | 2 | 5 | 866 | 0 | 626 | 4.13 (0.50–34.37) | 0 | 0.19 |
| Myositis | 2 | 3 | 798 | 1 | 596 | 1.81 (0.27–12.29) | 0 | 0.55 |
| Thyroiditis | 2 | 4 | 683 | 0 | 482 | 3.45 (0.39–30.27) | 0 | 0.26 |
| Ocular inflammatory toxicity | 1 | 3 | 393 | 0 | 394 | 7.02 (0.36–135.41) | NA | 0.2 |
| Encephalitis | 1 | 1 | 393 | 0 | 394 | 3.01 (0.12–73.60) | NA | 0.5 |
| Autoimmune hemolytic anemia | 1 | 1 | 393 | 1 | 394 | 1 (0.06–15.97) | NA | 1 |
| Vasculitis | 1 | 1 | 393 | 1 | 394 | 1 (0.06–15.97) | NA | 1 |
RR: Risk ratio.